These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

599 related articles for article (PubMed ID: 18036365)

  • 61. [JUPITER, what now?].
    Perna GP
    G Ital Cardiol (Rome); 2009 Dec; 10(11-12 Suppl 3):33S-38S. PubMed ID: 21298860
    [TBL] [Abstract][Full Text] [Related]  

  • 62. A tale of three labels: translating the JUPITER trial data into regulatory claims.
    Ridker PM
    Clin Trials; 2011 Aug; 8(4):417-22. PubMed ID: 21835857
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The high-dose rosuvastatin once weekly study (the HD-ROWS).
    Backes JM; Gibson CA; Ruisinger JF; Moriarty PM
    J Clin Lipidol; 2012; 6(4):362-7. PubMed ID: 22836073
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Statin therapy in primary prevention: new insights regarding women and the elderly.
    Harrington C; Horne A; Hasan RK; Blumenthal RS
    Am J Cardiol; 2010 Nov; 106(9):1357-9. PubMed ID: 21029838
    [No Abstract]   [Full Text] [Related]  

  • 65. Review of efficacy of rosuvastatin 5 mg.
    Teramoto T; Watkins C
    Int J Clin Pract; 2005 Jan; 59(1):92-101. PubMed ID: 15707472
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Efficacy and safety of rosuvastatin therapy for children with familial hypercholesterolemia.
    Avis HJ; Hutten BA; Gagné C; Langslet G; McCrindle BW; Wiegman A; Hsia J; Kastelein JJ; Stein EA
    J Am Coll Cardiol; 2010 Mar; 55(11):1121-6. PubMed ID: 20223367
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Clinical efficacy of rosuvastatin in lipid management in Chinese patients in Hong Kong.
    Lee VW; Chau TS; Leung VP; Lee KK; Tomlinson B
    Chin Med J (Engl); 2009 Dec; 122(23):2814-9. PubMed ID: 20092783
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Race, ethnicity, and the efficacy of rosuvastatin in primary prevention: the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial.
    Albert MA; Glynn RJ; Fonseca FA; Lorenzatti AJ; Ferdinand KC; MacFadyen JG; Ridker PM
    Am Heart J; 2011 Jul; 162(1):106-14.e2. PubMed ID: 21742096
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Letter by Wells and Eisenberg regarding article, "Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials".
    Wells MT; Eisenberg T
    Circulation; 2010 Dec; 122(23):e575; author reply e577. PubMed ID: 21135368
    [No Abstract]   [Full Text] [Related]  

  • 70. Effect of rosuvastatin on C-reactive protein and renal function in patients with chronic kidney disease.
    Verma A; Ranganna KM; Reddy RS; Verma M; Gordon NF
    Am J Cardiol; 2005 Nov; 96(9):1290-2. PubMed ID: 16253600
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Letter by Vos et al regarding article, "Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials".
    Vos E; Rose CP; Biron P
    Circulation; 2010 Dec; 122(23):e576; author reply e577. PubMed ID: 21135369
    [No Abstract]   [Full Text] [Related]  

  • 72. Impact of a compliance program on cholesterol control: results of the randomized ORBITAL study in 8108 patients treated with rosuvastatin.
    Willich SN; Englert H; Sonntag F; Völler H; Meyer-Sabellek W; Wegscheider K; Windler E; Katus H; Müller-Nordhorn J
    Eur J Cardiovasc Prev Rehabil; 2009 Apr; 16(2):180-7. PubMed ID: 19174696
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Kinesin-like protein 6 (KIF6) polymorphism and the efficacy of rosuvastatin in primary prevention.
    Ridker PM; MacFadyen JG; Glynn RJ; Chasman DI
    Circ Cardiovasc Genet; 2011 Jun; 4(3):312-7. PubMed ID: 21493817
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Cost-effectiveness of rosuvastatin for primary prevention of cardiovascular events according to Framingham Risk Score in patients with elevated C-reactive protein.
    MacDonald GP
    J Am Osteopath Assoc; 2010 Aug; 110(8):427-36. PubMed ID: 20805548
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Extreme all-cause mortality in JUPITER requires reexamination of vital records.
    Serebruany VL
    Cardiology; 2011; 120(2):84-8. PubMed ID: 22142620
    [TBL] [Abstract][Full Text] [Related]  

  • 76. A 12-week, prospective, open-label analysis of the effect of rosuvastatin on triglyceride-rich lipoprotein metabolism in patients with primary dyslipidemia.
    Kostapanos MS; Milionis HJ; Filippatos TD; Nakou ES; Bairaktari ET; Tselepis AD; Elisaf MS
    Clin Ther; 2007 Jul; 29(7):1403-14. PubMed ID: 17825691
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Rosuvastatin along the cardiovascular continuum: from JUPITER to AURORA.
    Barrios V; Escobar C
    Expert Rev Cardiovasc Ther; 2009 Nov; 7(11):1317-27. PubMed ID: 19900015
    [TBL] [Abstract][Full Text] [Related]  

  • 78. JUPITER study highlights value of anti-inflammatory action of rosuvastatin.
    Cardiovasc J Afr; 2009; 20(3):211. PubMed ID: 19575096
    [No Abstract]   [Full Text] [Related]  

  • 79. Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study.
    Alvarez-Sala LA; Cachofeiro V; Masana L; Suarez C; Pinilla B; Plana N; Trias F; Moreno MA; Gambus G; Lahera V; Pintó X
    Clin Ther; 2008 Jan; 30(1):84-97. PubMed ID: 18343245
    [TBL] [Abstract][Full Text] [Related]  

  • 80. [JUPITER can yield paradigmatic shift in the prevention of cardiovascular disease. Focus on inflammation as a risk factor].
    Olsson AG
    Lakartidningen; 2009 May 20-Jun 2; 106(21-22):1471-5. PubMed ID: 19579435
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.